#USA #San Francisco #Cell Therapy #Akadeum Life Sciences #Microbubble Technology

Akadeum Life Sciences Presents Microbubble Innovation at Biotech Showcase 2026

Akadeum Life Sciences, a trailblazer in cell separation technology, is set to reveal its groundbreaking microbubble platform at the upcoming Biotech Showcase on January 12, 2026, in San Francisco, CA. The focus of the presentation, led by CEO Brandon McNaughton, PhD, will be on how this innovative technology paves the way for scalable, efficient production of cell therapies that can significantly benefit larger populations of patients suffering from various conditions, including autoimmune diseases, solid tumors, and diabetes.

Revolutionary Microbubble Technology

Akadeum's microbubble technology stands out due to its ability to enable rapid and cost-effective manufacturing processes. The platform has been designed to address the pressing bottlenecks in the current cell therapy industry. Its approach allows for the creation of hundreds of thousands of cell therapy doses in a single year, thereby expanding access to these crucial treatments.

The unique feature of this technology is the deployment of buoyant microbubbles that facilitate the separation of unwanted cells. This gentler method not only maintains cell quality but also enhances their viability and potency. In comparison to conventional methods, Akadeum provides a more streamlined process that simplifies production and significantly reduces labor and capital costs. This remarkable capability is highlighted by a recent collaboration with Kure Cells, where Akadeum's platform was integrated into their IND application, resulting in the ability to manufacture cell therapies within just one day.

Economic Benefits

The economic advantages of Akadeum's microbubble technology cannot be overstated. By eliminating traditional cell separation equipment and reducing GMP (Good Manufacturing Practices) space requirements, manufacturers can experience a 40% overall reduction in costs. This includes factors such as labor efficiency and savings on capital investments. Data obtained through partnerships with industry leaders demonstrate that Akadeum achieves consistent performance even at scales exceeding 100 billion cells—an impressive feat that could transform the cell therapy landscape.

Regulatory Milestones

In late 2025, Akadeum reached a significant regulatory milestone by submitting a Type II Drug Master File (DMF) to the U.S. FDA. This submission ensures that their GMP BACS™ Microbubble Cell Separation products align with the necessary standards for cell and gene therapies. The DMF supports the rigorous compliance needed for developers looking to incorporate Akadeum's isolation kits into their regulated manufacturing processes. This step not only solidifies Akadeum’s commitment to quality but also enhances adoption confidence among potential users.

CEO Brandon McNaughton emphasized the importance of making effective cell therapies not only scalable but also accessible in outpatient settings. He noted, "Cell therapy is proven effective; now we must work toward making it widely available. Our technology supports this vision by enabling faster, more affordable treatments."

Presentation Details

Those interested in learning more can attend Akadeum's presentation on January 12 at the Biotech Showcase, scheduled for 10:30 AM in Franciscan B (Ballroom Level). This event is known as a premier meeting point for biotechnology companies and investors, nurturing partnerships and innovation.

About Akadeum Life Sciences

Akadeum Life Sciences is at the forefront of advancing cell separation technologies. With its buoyant microbubble platform, the company aims to achieve higher yields and enhanced process simplicity across diverse life science applications. Its mission is to enhance human health by developing innovative separation technologies, ultimately enabling breakthroughs in both diagnostics and therapeutics. For more information, visit www.akadeum.com.

In summary, Akadeum's innovative approach presents a promising future for cell therapy manufacturing, bringing about vital advancements that can lead to better health outcomes for patients worldwide.